Published in Anticancer Agents Med Chem on June 01, 2011
Interaction of tumor cells with the microenvironment. Cell Commun Signal (2011) 1.38
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol (2013) 1.07
NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis (2013) 0.97
Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Dig Dis Sci (2012) 0.90
Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy. Cancer Microenviron (2012) 0.88
Vitamin D receptor signaling and pancreatic cancer cell EMT. Curr Pharm Des (2015) 0.75
Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg (2007) 1.79
An intravital model to monitor steps of metastatic tumor cell adhesion within the hepatic microcirculation. J Gastrointest Surg (2003) 1.75
Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision. Onkologie (2005) 1.42
Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer (2004) 1.29
A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer (2006) 1.16
Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep (2006) 1.10
Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer (2007) 1.06
An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl) (2009) 1.05
Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis (2011) 1.05
VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery (2005) 1.04
An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas (2003) 1.01
Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature. Int J Colorectal Dis (2010) 0.96
Beyond epithelial to mesenchymal transition: a novel role for the transcription factor Snail in inflammation and wound healing. J Gastrointest Surg (2009) 0.96
Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg (2002) 0.94
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med (2005) 0.92
Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer (2002) 0.91
Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. Int J Colorectal Dis (2005) 0.85
Gallbladder involvement of Henoch-Schönlein purpura mimicking acute acalculous cholecystitis. Digestion (2004) 0.84
Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin Exp Metastasis (2002) 0.84
Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg (2003) 0.84
Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis (2011) 0.82
An orthotopic nude mouse model for preclinical research of gastric cardia cancer. Int J Colorectal Dis (2008) 0.82
Capsule endoscopy in small-bowel surveillance of patients with hereditary polyposis syndromes. Int J Colorectal Dis (2010) 0.82
Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer. J Gastrointest Surg (2005) 0.81
Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease. Int J Colorectal Dis (2009) 0.79
Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer. Acta Radiol (2013) 0.78
Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555 C. Invest Radiol (2009) 0.78
Pelvic sidewall involvement in recurrent rectal cancer. Int J Colorectal Dis (2003) 0.78
Association between activation of atypical NF-kappaB1 p105 signaling pathway and nuclear beta-catenin accumulation in colorectal carcinoma. Mol Carcinog (2010) 0.77
Dendritic cells from human mesenteric lymph nodes in inflammatory and non-inflammatory bowel diseases: subsets and function of plasmacytoid dendritic cells. Immunology (2013) 0.77
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg (2007) 0.77
Gadofluorine M-enhanced magnetic resonance imaging of inflammatory bowel disease: quantitative analysis and histologic correlation in a rat model. Invest Radiol (2011) 0.77
Pilot study of bipolar radiofrequency-induced anastomotic thermofusion-exploration of therapy parameters ex vivo. Int J Colorectal Dis (2009) 0.77
Recombinant human beta 2-defensin fusion proteins as a tool to investigate defensin structure and function in small human intestinal tissue samples. Inflamm Res (2012) 0.75
HLA-A2 expression, stage, and survival in colorectal cancer. Int J Colorectal Dis (2008) 0.75
[Surgical quality--transparency of surgical quality--plea for new openness]. Zentralbl Chir (2008) 0.75
A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbecks Arch Surg (2011) 0.75
Improving results of elective abdominal aortic aneurysm repair at a low-volume hospital by risk-adjusted selection of treatment in the endovascular era. Cardiovasc Intervent Radiol (2009) 0.75